Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Chardan Capital Markets Upgrades Amicus Therapeutics (FOLD) to Buy
October 5, 2015 6:35 AM EDTChardan Capital Markets upgraded Amicus Therapeutics (NASDAQ: FOLD) from Neutral to Buy with a price target of $8.00.
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $6.39 yesterday.
... MoreAmicus Therapeutics (FOLD) PT Cut to $13 at Cowen on Galafold NDA Delay
October 5, 2015 6:31 AM EDTCowen analyst Ritu Baral lowered his price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $27.00) after the Galafold NDA was delayed but maintained an Outperform rating.
Baral commente, "After receipt of minutes from the Sept. pre-NDA meeting of Galafold for Fabry's,... More
Amicus Therapeutics (FOLD) Slammed Following Migalastat Monotherapy NDA Update
October 2, 2015 9:31 AM EDTAmicus Therapeutics (NASDAQ: FOLD) shares are getting slammed Friday after the company said it does not anticipate being in a position to submit the NDA for migalastat monotherapy in the United States by the end of this year. The stock is down 60 percent at the start.
... MoreAmicus Therapeutics (FOLD) Unlikley to Submit NDA for Migalastat Monotherapy This Year
October 2, 2015 9:04 AM EDTAmicus Therapeutics (Nasdaq: FOLD) announced additional regulatory guidance from the U.S. Food and Drug Administration (FDA) on the oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease.
Amicus has received final FDA minutes from the September pre-NDA meeting and has conducted... More
